Friday, June 19, 2026
🇺🇸 FDA
Pharma Manufacturing World pharmaceutical event banner
← Back to Events
Tier 1 Global Networking: High MANUFACTURING CONCLUDED

Pharma Manufacturing World — 2026 — Boston Marriott Copley Place, Boston, United States

Premier gathering for pharmaceutical manufacturing leaders to explore innovative strategies, emerging trends, and best practices.

Boston Marriott Copley Place, Boston, United States May 18 – May 20, 2026
10 Presentations
4 Companies
9 Drugs
All Events

Presentation data updated Jun 13, 2026, 5:35 AM UTC

Nova Event Impact Score
64 /100
  • Media coverage 20/20
  • Speaker quality 14/20
  • Pipeline relevance 2/20
  • Historical influence 20/20
  • Company participation 8/20

Key Takeaways

Key Themes

manufacturingNot specifiedPipeline announcementsPartnership deals

Key Companies

Bristol Myers SquibbNovartisAnthos Therapeutics (Novartis)AstraZeneca

Key Drugs

zigakibartadagrasibcamizestrantnivolumabnivolumab + relatlimab

Key Markets

US Americas

Key Opportunities

Partnership dealsLicensing discussionsVendor selection
Best for
Investors & analysts

Key Data to Watch

Presentations ranked by investor impact score

PRESENTATION

abelacimab (SPAF) phase 3 readout

Anthos Therapeutics (Novartis) abelacimab Phase Iii Stroke prevention in atrial fibrillation
INVESTOR IMPACT: ★★★★☆ 4/5
PRESENTATION

SERENA-6 first data readout

AstraZeneca$AZN camizestrant Phase Iii Breast cancer
Event presentation hub → Company at this event →
INVESTOR IMPACT: ★★★★☆ 4/5
PRESENTATION

Krazati (adagrasib) update

Bristol Myers Squibb$BMY adagrasib(Krazati) Phase Iii Non-small cell lung cancer
Event presentation hub → Company at this event →
INVESTOR IMPACT: ★★★★☆ 4/5
PRESENTATION

Opdivo (nivolumab) clinical trial update

Bristol Myers Squibb$BMY nivolumab(Opdivo) Phase Iii Various cancers
Event presentation hub → Company at this event →
INVESTOR IMPACT: ★★★★☆ 4/5
PRESENTATION

Nivo+Rela HD (nivolumab + relatlimab) phase 3 readout

Bristol Myers Squibb$BMY nivolumab + relatlimab(Opdualag) Phase Iii Melanoma
Event presentation hub → Company at this event →
INVESTOR IMPACT: ★★★★☆ 4/5
PRESENTATION

remibrutinib (MS) phase 3 readout

Novartis$NVS remibrutinib Phase Iii Multiple sclerosis
Event presentation hub → Company at this event →
INVESTOR IMPACT: ★★★★☆ 4/5
PRESENTATION

zigakibart (IgAN) phase 3 readout

Novartis$NVS zigakibart Phase Iii IgA nephropathy
Event presentation hub → Company at this event →
INVESTOR IMPACT: ★★★★☆ 4/5
PRESENTATION

pelacarsen (CVRR-Lp(a)) phase 3 readout

Novartis$NVS pelacarsen Phase Iii Cardiovascular risk reduction (Lp(a) elevation)
Company at this event →
INVESTOR IMPACT: ★★★★☆ 4/5
PRESENTATION

AR LDD (androgen receptor degrader) phase 2 readout

Bristol Myers Squibb$BMY unknown(AR LDD) Phase Ii Prostate cancer
Company at this event →
INVESTOR IMPACT: ★★☆☆☆ 2/5
ORAL

Short talks selected from submitted abstracts: Latest research in Pharmaceutics, Biopharmaceutics

INVESTOR IMPACT: ★☆☆☆☆ 1/5